Today at #ASCOQLTY25: lab members Jared Gregston (MS4 @OUCollegeofMed) & Maya Stephens (@MayaJanel; MS2 @MCG_AUG) present their accepted abstracts (with caffeinated assistance)! #RadOnc

DrMcClellandLab's tweet image. Today at #ASCOQLTY25: lab members Jared Gregston (MS4 @OUCollegeofMed) & Maya Stephens (@MayaJanel; MS2 @MCG_AUG) present their accepted abstracts (with caffeinated assistance)!
#RadOnc

A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery? In some ways, this review attempts to answer that very question. This table provides a synopsis of its contents. #radonc

CTuscanoMD's tweet image. A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery?
In some ways, this review attempts to answer that very question.
This table provides a synopsis of its contents. #radonc…

Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key. #OpenAccess review by Andratschke et al: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert #RadOnc

CACancerJournal's tweet image. Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key. 

#OpenAccess review by Andratschke et al:
acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

@OncoAlert #RadOnc

🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer! Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus #ASTRO25 #RadOnc

_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc

WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone ✅ TTFields delays intracranial progression (HR 0.72, p=0.044) 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy (HR 0.63) ❌No QoL / cognition decline; AEs mild skin #ASTRO25 #RadOnc

_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…

🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p<0.001) with minimal added adverse events. 🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

Great turnout to learn about cancer biology science @SitemanCenter Research Symposium! The #radonc labs of @JulieSchwarz14 & @VKapoor25 were well-represented at the podium.

WashUMedRadOnc's tweet image. Great turnout to learn about cancer biology science @SitemanCenter Research Symposium! 
The #radonc labs of @JulieSchwarz14 &amp;amp; @VKapoor25 were well-represented at the podium.
WashUMedRadOnc's tweet image. Great turnout to learn about cancer biology science @SitemanCenter Research Symposium! 
The #radonc labs of @JulieSchwarz14 &amp;amp; @VKapoor25 were well-represented at the podium.

Great to have the chance to meet with the amazing #RadOnc residents @UofTDRO during their academic half day and then enjoy a fun lunch together @ldawsonmd

DKirschMDPhD's tweet image. Great to have the chance to meet with the amazing #RadOnc residents @UofTDRO during their academic half day and then enjoy a fun lunch together

@ldawsonmd

Truly an honor to be invited to Mt Sinai to speak, 9 years after finishing my residency @ken4englewood @MSROResidents #radonc #fullcircle

MKnoll_MD's tweet image. Truly an honor to be invited to Mt Sinai to speak, 9 years after finishing my residency 

@ken4englewood @MSROResidents

#radonc #fullcircle

Super excited to introduce #radonc who will be joining ⁦@CleClinicMD⁩ as staff in 2026- Drs. Meena Bedi, Saleh Hatoum, Mustafa Basree, Jenna Kocsis & Osagie Igiebor!! ⁦@ARRO_org#CleClinicCancer

DrJohnSuh's tweet image. Super excited to introduce #radonc who will be joining ⁦@CleClinicMD⁩ as staff in 2026- Drs. Meena Bedi, Saleh Hatoum, Mustafa Basree, Jenna Kocsis &amp;amp; Osagie Igiebor!! ⁦@ARRO_org⁩ #CleClinicCancer

Wonderful to have the talented Dr. Nancy Lee from @MSK_RadOnc visit us @COH_RadOnc. 🙏Nancy for the tour de force work you have done on de-escalation in HNSCC & hypoxia imaging biomarker driven approaches. Let's keep pushing the field forward to bring more biology to #radonc ‼️

TeWilliamsMD's tweet image. Wonderful to have the talented Dr. Nancy Lee from @MSK_RadOnc visit us @COH_RadOnc.  🙏Nancy for the tour de force work you have done on de-escalation in HNSCC &amp;amp; hypoxia imaging biomarker driven approaches.  Let&apos;s keep pushing the field forward to bring more biology to #radonc ‼️

I had an amazing time returning to the old residency stomping grounds and seeing the new facility as visiting professor and BCM #radonc. Met a great group of residents and discussed optimization of #brachytherapy workflows!

AndrewFarach's tweet image. I had an amazing time returning to the old residency stomping grounds and seeing the new facility as visiting professor and BCM #radonc. Met a great group of residents and discussed optimization of #brachytherapy workflows!

Outstanding member @EnaOboh presenting her work as our first #ASCOQLTY25 abstract! #RadOnc #GBM #FinancialToxicity #WomenWhoCurie

DrMcClellandLab's tweet image. Outstanding member @EnaOboh presenting her work as our first #ASCOQLTY25 abstract!
#RadOnc 
#GBM
#FinancialToxicity
#WomenWhoCurie
DrMcClellandLab's tweet image. Outstanding member @EnaOboh presenting her work as our first #ASCOQLTY25 abstract!
#RadOnc 
#GBM
#FinancialToxicity
#WomenWhoCurie
DrMcClellandLab's tweet image. Outstanding member @EnaOboh presenting her work as our first #ASCOQLTY25 abstract!
#RadOnc 
#GBM
#FinancialToxicity
#WomenWhoCurie
DrMcClellandLab's tweet image. Outstanding member @EnaOboh presenting her work as our first #ASCOQLTY25 abstract!
#RadOnc 
#GBM
#FinancialToxicity
#WomenWhoCurie

Work outfit. Because even on cloudy rainy days you gotta bring patients your own sunshine ☀️😎🧬☢️. #RadOnc #gyncsm

IvyRadOncMD's tweet image. Work outfit. Because even on cloudy rainy days you gotta bring patients your own sunshine ☀️😎🧬☢️. #RadOnc #gyncsm

Artificial Intelligence: Aiding Precision and Practice in Radiation Oncology 🔗 ow.ly/Gh4c50X9svV #AI #RadOnc #RadiationOncology

Applied_RadOnc's tweet image. Artificial Intelligence: Aiding Precision and Practice in Radiation Oncology

🔗 ow.ly/Gh4c50X9svV

#AI #RadOnc #RadiationOncology

The @USCBO Congressional Budget Office released "Growth in the 340B Drug Pricing Program" On Sept 2, 2025 cbo.gov/publication/60… For comparison, I made a graph of "Growth in Radiation Oncology #radonc Spending" over the same time period

toddscarbrough's tweet image. The @USCBO Congressional Budget Office released 

&quot;Growth in the 340B Drug Pricing Program&quot;

On Sept 2, 2025
cbo.gov/publication/60…

For comparison, I made a graph of

&quot;Growth in Radiation Oncology #radonc Spending&quot; over the same time period

Interesting data from MSK on a cohort of pts treated w photon or proton ☢️ for oropharynx cancer - proton therapy was assoc w ⬆️ risk of osteoradionecrosis These data help w/ shared decision making for use of protons in #hncsm #radonc #ASTRO25

RadOncDoc_Niema's tweet image. Interesting data from MSK on a cohort of pts treated w photon or proton ☢️ for oropharynx cancer - proton therapy was assoc w ⬆️ risk of osteoradionecrosis 

These data help w/ shared decision making for use of protons in #hncsm 

#radonc #ASTRO25

I love #radonc and radiosurgery because of the empiric outcomes. But we need to stop claiming <1 mm accuracy when our tech specs say the imaging has 2 mm resolution. Maybe can claim specifically <1 mm setup error…

A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery? In some ways, this review attempts to answer that very question. This table provides a synopsis of its contents. #radonc

CTuscanoMD's tweet image. A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery?
In some ways, this review attempts to answer that very question.
This table provides a synopsis of its contents. #radonc…


A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery? In some ways, this review attempts to answer that very question. This table provides a synopsis of its contents. #radonc

CTuscanoMD's tweet image. A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery?
In some ways, this review attempts to answer that very question.
This table provides a synopsis of its contents. #radonc…

We have theoretical physicists. Do we have theoretical radiation oncologists? #radonc #radmed @NehaVapiwala @HenningWillers @NiuSanford @sueyom @rweichselbaum @SameerKeoleMD @pipcosper @KimpleRandall


"When Disaster Strikes: Maintaining Cancer Care During Catastrophic Events" Proud of this panel @ASCO #ASCOQLTY25 including 3⃣ #radonc. Radiation care is a vital cancer treatment involving DAILY visits; disruptions during catastrophic events disproportionately effects our care.

fumikochino's tweet image. &quot;When Disaster Strikes: Maintaining Cancer Care During Catastrophic Events&quot; 

Proud of this panel @ASCO #ASCOQLTY25 including 3⃣ #radonc. Radiation care is a vital cancer treatment involving DAILY visits; disruptions during catastrophic events disproportionately effects our care.

☢️ Radiation Oncologist Prof Sandra Turner & Clinical Oncologist Dr Katie Wakeham talk about the purpose of World Radiotherapy Awareness Day & the Global Movement to make sure cancer patients get access to #radiotherapy if needed. @WorldRTDay #radonc #rtt youtu.be/TvJakDH1DSo

JulieMcCrossin's tweet card. World Radiotherapy Awareness Day - Interview with Prof Sandra Turner...

youtube.com

YouTube

World Radiotherapy Awareness Day - Interview with Prof Sandra Turner...


Work by Drs @KShah0520 & @TrishaSantosMD using the NIS sample showed incarcerated adults in the US are 92% more likely to die from their cancer than the non-incarcerated. Cancer is the #1 cause of death in hospitalized incarcerated patients‼️‼️ #ASCOQLTY25

anhbl9's tweet image. Work by Drs @KShah0520 &amp;amp; @TrishaSantosMD using the NIS sample showed incarcerated adults in the US are 92% more likely to die from their cancer than the non-incarcerated.

Cancer is the #1 cause of death in hospitalized incarcerated patients‼️‼️

#ASCOQLTY25
anhbl9's tweet image. Work by Drs @KShah0520 &amp;amp; @TrishaSantosMD using the NIS sample showed incarcerated adults in the US are 92% more likely to die from their cancer than the non-incarcerated.

Cancer is the #1 cause of death in hospitalized incarcerated patients‼️‼️

#ASCOQLTY25
anhbl9's tweet image. Work by Drs @KShah0520 &amp;amp; @TrishaSantosMD using the NIS sample showed incarcerated adults in the US are 92% more likely to die from their cancer than the non-incarcerated.

Cancer is the #1 cause of death in hospitalized incarcerated patients‼️‼️

#ASCOQLTY25


Fantastic mentee, @DrMcClellandLab member & @OUCollegeofMed MS4 Jared Gregston presenting his @ConquerCancerFd Merit Award-winning work on the rate & quality of #BreastCancer care following initial diagnosis at #ASCOQLTY25! #RadOnc #bcsm #RepresentationMatters #Match2026

TheDrWood's tweet image. Fantastic mentee, @DrMcClellandLab member &amp;amp; @OUCollegeofMed MS4 Jared Gregston presenting his @ConquerCancerFd Merit Award-winning work on the rate &amp;amp; quality of #BreastCancer care following initial diagnosis at #ASCOQLTY25!
#RadOnc
#bcsm
#RepresentationMatters
#Match2026
TheDrWood's tweet image. Fantastic mentee, @DrMcClellandLab member &amp;amp; @OUCollegeofMed MS4 Jared Gregston presenting his @ConquerCancerFd Merit Award-winning work on the rate &amp;amp; quality of #BreastCancer care following initial diagnosis at #ASCOQLTY25!
#RadOnc
#bcsm
#RepresentationMatters
#Match2026
TheDrWood's tweet image. Fantastic mentee, @DrMcClellandLab member &amp;amp; @OUCollegeofMed MS4 Jared Gregston presenting his @ConquerCancerFd Merit Award-winning work on the rate &amp;amp; quality of #BreastCancer care following initial diagnosis at #ASCOQLTY25!
#RadOnc
#bcsm
#RepresentationMatters
#Match2026

Lab members Jared Gregston, Dr. @TheDrWood, & @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. Congrats to Jared on the Merit Award!

DrMcClellandLab's tweet image. Lab members Jared Gregston, Dr. @TheDrWood, &amp;amp; @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. 
Congrats to Jared on the Merit Award!
DrMcClellandLab's tweet image. Lab members Jared Gregston, Dr. @TheDrWood, &amp;amp; @MayaJanel in front of their #RadOnc #BreastCancer work at #ASCOQLTY25. 
Congrats to Jared on the Merit Award!

Today at #ASCOQLTY25: lab members Jared Gregston (MS4 @OUCollegeofMed) & Maya Stephens (@MayaJanel; MS2 @MCG_AUG) present their accepted abstracts (with caffeinated assistance)! #RadOnc

DrMcClellandLab's tweet image. Today at #ASCOQLTY25: lab members Jared Gregston (MS4 @OUCollegeofMed) &amp;amp; Maya Stephens (@MayaJanel; MS2 @MCG_AUG) present their accepted abstracts (with caffeinated assistance)!
#RadOnc

🌟 A heartfelt gratitude to the incredible #radonc team at the Miami Cancer Institute. A special thanks to Drs. Matthew Hall, Minesh Mehta, Alonso Gutierrez, wonderful admins Marina & Juliet, & the whole team for the warm invitation & exceptional hospitality during my visit.

NataliyaMedPhys's tweet image. 🌟 A heartfelt gratitude to the incredible #radonc team at the Miami Cancer Institute. A special thanks to Drs. Matthew Hall, Minesh Mehta, Alonso Gutierrez, wonderful admins Marina &amp;amp; Juliet, &amp;amp; the whole team for the warm invitation &amp;amp; exceptional hospitality during my visit.
NataliyaMedPhys's tweet image. 🌟 A heartfelt gratitude to the incredible #radonc team at the Miami Cancer Institute. A special thanks to Drs. Matthew Hall, Minesh Mehta, Alonso Gutierrez, wonderful admins Marina &amp;amp; Juliet, &amp;amp; the whole team for the warm invitation &amp;amp; exceptional hospitality during my visit.

Beyond grateful to @RTOGFoundation for this unparalleled opportunity to work with, and learn about the inner workings of, a core founding member of @NRGonc with more than six decades of history pioneering the standards of care in #radonc! @wallyjc @KHigginsMD @Qle_stanford

We cannot be more grateful for our RTOG Foundation Communications Interns each year that help our Communications Committee expand the reach of the important messages RTOGF shares. Learn more about our 2025-2026 interns, @djlee714 & @AlexisNarvaezMD here: ow.ly/Euji50X7PYI

RTOGFoundation's tweet image. We cannot be more grateful for our RTOG Foundation Communications Interns each year that help our Communications Committee expand the reach of the important messages RTOGF shares. Learn more about our 2025-2026 interns, @djlee714 &amp;amp; @AlexisNarvaezMD here: ow.ly/Euji50X7PYI


Tomorrow 10/11/2025 11:50AM EST I will be presenting my locoregional perspective of the evolution of Breast Cancer treatment. The #SurgOnc and #RadOnc perspective. Full #Spanish talk as part of my #GlobalHealth #LatAm #efforts as an #international accredited #surgonc #faculty.…

AlexisNarvaezMD's tweet image. Tomorrow 10/11/2025 11:50AM EST I will be presenting my locoregional perspective of the evolution of Breast Cancer treatment. The #SurgOnc and #RadOnc perspective. Full #Spanish talk as part of my #GlobalHealth #LatAm #efforts as an #international accredited #surgonc #faculty.…
AlexisNarvaezMD's tweet image. Tomorrow 10/11/2025 11:50AM EST I will be presenting my locoregional perspective of the evolution of Breast Cancer treatment. The #SurgOnc and #RadOnc perspective. Full #Spanish talk as part of my #GlobalHealth #LatAm #efforts as an #international accredited #surgonc #faculty.…
AlexisNarvaezMD's tweet image. Tomorrow 10/11/2025 11:50AM EST I will be presenting my locoregional perspective of the evolution of Breast Cancer treatment. The #SurgOnc and #RadOnc perspective. Full #Spanish talk as part of my #GlobalHealth #LatAm #efforts as an #international accredited #surgonc #faculty.…
AlexisNarvaezMD's tweet image. Tomorrow 10/11/2025 11:50AM EST I will be presenting my locoregional perspective of the evolution of Breast Cancer treatment. The #SurgOnc and #RadOnc perspective. Full #Spanish talk as part of my #GlobalHealth #LatAm #efforts as an #international accredited #surgonc #faculty.…

Great turnout to learn about cancer biology science @SitemanCenter Research Symposium! The #radonc labs of @JulieSchwarz14 & @VKapoor25 were well-represented at the podium.

WashUMedRadOnc's tweet image. Great turnout to learn about cancer biology science @SitemanCenter Research Symposium! 
The #radonc labs of @JulieSchwarz14 &amp;amp; @VKapoor25 were well-represented at the podium.
WashUMedRadOnc's tweet image. Great turnout to learn about cancer biology science @SitemanCenter Research Symposium! 
The #radonc labs of @JulieSchwarz14 &amp;amp; @VKapoor25 were well-represented at the podium.

Outstanding member @EnaOboh presenting her work as our first #ASCOQLTY25 abstract! #RadOnc #GBM #FinancialToxicity #WomenWhoCurie

DrMcClellandLab's tweet image. Outstanding member @EnaOboh presenting her work as our first #ASCOQLTY25 abstract!
#RadOnc 
#GBM
#FinancialToxicity
#WomenWhoCurie
DrMcClellandLab's tweet image. Outstanding member @EnaOboh presenting her work as our first #ASCOQLTY25 abstract!
#RadOnc 
#GBM
#FinancialToxicity
#WomenWhoCurie
DrMcClellandLab's tweet image. Outstanding member @EnaOboh presenting her work as our first #ASCOQLTY25 abstract!
#RadOnc 
#GBM
#FinancialToxicity
#WomenWhoCurie
DrMcClellandLab's tweet image. Outstanding member @EnaOboh presenting her work as our first #ASCOQLTY25 abstract!
#RadOnc 
#GBM
#FinancialToxicity
#WomenWhoCurie

Artificial Intelligence: Aiding Precision and Practice in Radiation Oncology 🔗 ow.ly/Gh4c50X9svV #AI #RadOnc #RadiationOncology

Applied_RadOnc's tweet image. Artificial Intelligence: Aiding Precision and Practice in Radiation Oncology

🔗 ow.ly/Gh4c50X9svV

#AI #RadOnc #RadiationOncology

WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone ✅ TTFields delays intracranial progression (HR 0.72, p=0.044) 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy (HR 0.63) ❌No QoL / cognition decline; AEs mild skin #ASTRO25 #RadOnc

_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…
_ShankarSiva's tweet image. WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone
✅ TTFields delays intracranial progression (HR 0.72, p=0.044)
 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy  (HR 0.63)
 ❌No QoL / cognition decline; AEs mild skin
#ASTRO25 #RadOnc…

Super excited to introduce #radonc who will be joining ⁦@CleClinicMD⁩ as staff in 2026- Drs. Meena Bedi, Saleh Hatoum, Mustafa Basree, Jenna Kocsis & Osagie Igiebor!! ⁦@ARRO_org#CleClinicCancer

DrJohnSuh's tweet image. Super excited to introduce #radonc who will be joining ⁦@CleClinicMD⁩ as staff in 2026- Drs. Meena Bedi, Saleh Hatoum, Mustafa Basree, Jenna Kocsis &amp;amp; Osagie Igiebor!! ⁦@ARRO_org⁩ #CleClinicCancer

🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p<0.001) with minimal added adverse events. 🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
_ShankarSiva's tweet image. 🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p&amp;lt;0.001) with minimal added adverse events. 
🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer! Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) & MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus #ASTRO25 #RadOnc

_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc
_ShankarSiva's tweet image. 🚨 NRGGU006: prospectively validated 🎯 PAM50 = predictive 🔬 biomarker for ARPI in #ProstateCancer!

Adding apalutamide 💊 to salvage RT (no ADT) boosted 5-yr bPFS (72% vs 54%) &amp;amp; MFS (95% vs 82%) in luminal B tumors ➡️ no benefit in others. @DrSpratticus 
#ASTRO25 #RadOnc

Truly an honor to be invited to Mt Sinai to speak, 9 years after finishing my residency @ken4englewood @MSROResidents #radonc #fullcircle

MKnoll_MD's tweet image. Truly an honor to be invited to Mt Sinai to speak, 9 years after finishing my residency 

@ken4englewood @MSROResidents

#radonc #fullcircle

Happy to share that my K08 award scored in the 2nd percentile on our first submission- grateful for all of our collaborators and excited for the work to come! #radonc @UMRogelCancer @MichRadOncRes @YatrikShahLab @DanWahlMD @Dan_ChangMD @UMichRadOnc

ameerelaimy's tweet image. Happy to share that my K08 award scored in the 2nd percentile on our first submission- grateful for all of our collaborators and excited for the work to come! #radonc @UMRogelCancer @MichRadOncRes @YatrikShahLab @DanWahlMD @Dan_ChangMD @UMichRadOnc

Today at #ASCOQLTY25: lab members Jared Gregston (MS4 @OUCollegeofMed) & Maya Stephens (@MayaJanel; MS2 @MCG_AUG) present their accepted abstracts (with caffeinated assistance)! #RadOnc

DrMcClellandLab's tweet image. Today at #ASCOQLTY25: lab members Jared Gregston (MS4 @OUCollegeofMed) &amp;amp; Maya Stephens (@MayaJanel; MS2 @MCG_AUG) present their accepted abstracts (with caffeinated assistance)!
#RadOnc

Hanging out with the ⁦@MDAndersonNews#radonc residents at the after party. #ASTRO25@PrajnanDasMD⁩ ⁦@ChelseaPinnix⁩ ⁦@yogagirldd

ACKoongMDPhD's tweet image. Hanging out with the ⁦@MDAndersonNews⁩ #radonc residents at the after party. #ASTRO25 ⁦@PrajnanDasMD⁩ ⁦@ChelseaPinnix⁩ ⁦@yogagirldd⁩

Great to have the chance to meet with the amazing #RadOnc residents @UofTDRO during their academic half day and then enjoy a fun lunch together @ldawsonmd

DKirschMDPhD's tweet image. Great to have the chance to meet with the amazing #RadOnc residents @UofTDRO during their academic half day and then enjoy a fun lunch together

@ldawsonmd

A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery? In some ways, this review attempts to answer that very question. This table provides a synopsis of its contents. #radonc

CTuscanoMD's tweet image. A few years ago, @rweichselbaum posed—ironically, but not entirely so—the question: what is the difference between radiotherapy and radiosurgery?
In some ways, this review attempts to answer that very question.
This table provides a synopsis of its contents. #radonc…

Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key. #OpenAccess review by Andratschke et al: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert #RadOnc

CACancerJournal's tweet image. Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT &amp;amp; SBRT. Multidisciplinary care, imaging, and innovation are key. 

#OpenAccess review by Andratschke et al:
acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

@OncoAlert #RadOnc

I had an amazing time returning to the old residency stomping grounds and seeing the new facility as visiting professor and BCM #radonc. Met a great group of residents and discussed optimization of #brachytherapy workflows!

AndrewFarach's tweet image. I had an amazing time returning to the old residency stomping grounds and seeing the new facility as visiting professor and BCM #radonc. Met a great group of residents and discussed optimization of #brachytherapy workflows!

So incredibly excited to share that I’m joining @ClevelandClinic as staff #RadOnc next year. 🌟 It’s been a fantastic training experience at @UW_RadoncDHO, though we’re happy to move back home. We made it, mom. 😊 @DrJohnSuh @CleClinicMD #ASTRO25

mustafabasree's tweet image. So incredibly excited to share that I’m joining @ClevelandClinic as staff #RadOnc next year. 🌟 

It’s been a fantastic training experience at @UW_RadoncDHO, though we’re happy to move back home.

We made it, mom. 😊

@DrJohnSuh @CleClinicMD #ASTRO25

Great turnout to learn about cancer biology science @SitemanCenter Research Symposium! The #radonc labs of @JulieSchwarz14 & @VKapoor25 were well-represented at the podium.

WashUMedRadOnc's tweet image. Great turnout to learn about cancer biology science @SitemanCenter Research Symposium! 
The #radonc labs of @JulieSchwarz14 &amp;amp; @VKapoor25 were well-represented at the podium.
WashUMedRadOnc's tweet image. Great turnout to learn about cancer biology science @SitemanCenter Research Symposium! 
The #radonc labs of @JulieSchwarz14 &amp;amp; @VKapoor25 were well-represented at the podium.

Wonderful to have the talented Dr. Nancy Lee from @MSK_RadOnc visit us @COH_RadOnc. 🙏Nancy for the tour de force work you have done on de-escalation in HNSCC & hypoxia imaging biomarker driven approaches. Let's keep pushing the field forward to bring more biology to #radonc ‼️

TeWilliamsMD's tweet image. Wonderful to have the talented Dr. Nancy Lee from @MSK_RadOnc visit us @COH_RadOnc.  🙏Nancy for the tour de force work you have done on de-escalation in HNSCC &amp;amp; hypoxia imaging biomarker driven approaches.  Let&apos;s keep pushing the field forward to bring more biology to #radonc ‼️

Honored to train at ⁦@MSKCancerCenter#radonc alongside experts, change makers, and good people 🤩 #ASTRO2025@ASTRO_org⁩ ⁦@DanielGorovets⁩ ⁦@seanmmcbride⁩ ⁦@KaitlynLapen⁩ ⁦@MSK_RadOnc⁩ Thank you to Melissa and Amelia for setting this up

EChrisDee's tweet image. Honored to train at ⁦@MSKCancerCenter⁩ #radonc alongside experts, change makers, and good people 🤩

#ASTRO2025 ⁦@ASTRO_org⁩ 

⁦@DanielGorovets⁩ ⁦@seanmmcbride⁩ ⁦@KaitlynLapen⁩ ⁦@MSK_RadOnc⁩ 

Thank you to Melissa and Amelia for setting this up

The @USCBO Congressional Budget Office released "Growth in the 340B Drug Pricing Program" On Sept 2, 2025 cbo.gov/publication/60… For comparison, I made a graph of "Growth in Radiation Oncology #radonc Spending" over the same time period

toddscarbrough's tweet image. The @USCBO Congressional Budget Office released 

&quot;Growth in the 340B Drug Pricing Program&quot;

On Sept 2, 2025
cbo.gov/publication/60…

For comparison, I made a graph of

&quot;Growth in Radiation Oncology #radonc Spending&quot; over the same time period

Juliane Horner-Rieber presented a timely systematic review & meta-analysis comparing moderate hypofractionation vs 2 Gy/fx for RNI & PMRT #ASTRO25 🟰 Oncological outcomes 🔒 Comparable safety ✅ Moderate hypo standard of care #radonc #breastcancer #OncoAlert @OncoAlert

Icro_Meattini's tweet image. Juliane Horner-Rieber presented a timely systematic review &amp;amp; meta-analysis comparing moderate hypofractionation vs 2 Gy/fx for RNI &amp;amp; PMRT #ASTRO25

🟰 Oncological outcomes
🔒 Comparable safety
✅ Moderate hypo standard of care

#radonc #breastcancer #OncoAlert @OncoAlert
Icro_Meattini's tweet image. Juliane Horner-Rieber presented a timely systematic review &amp;amp; meta-analysis comparing moderate hypofractionation vs 2 Gy/fx for RNI &amp;amp; PMRT #ASTRO25

🟰 Oncological outcomes
🔒 Comparable safety
✅ Moderate hypo standard of care

#radonc #breastcancer #OncoAlert @OncoAlert
Icro_Meattini's tweet image. Juliane Horner-Rieber presented a timely systematic review &amp;amp; meta-analysis comparing moderate hypofractionation vs 2 Gy/fx for RNI &amp;amp; PMRT #ASTRO25

🟰 Oncological outcomes
🔒 Comparable safety
✅ Moderate hypo standard of care

#radonc #breastcancer #OncoAlert @OncoAlert
Icro_Meattini's tweet image. Juliane Horner-Rieber presented a timely systematic review &amp;amp; meta-analysis comparing moderate hypofractionation vs 2 Gy/fx for RNI &amp;amp; PMRT #ASTRO25

🟰 Oncological outcomes
🔒 Comparable safety
✅ Moderate hypo standard of care

#radonc #breastcancer #OncoAlert @OncoAlert

My ❤️ always leaves happier after leaving @ASTRO_org conferences #ASTRO25 had many great things, but the best part was the people 👯‍♀️ 🙏🏻 you again to @ARRO_org for the Resident Educator of the year award! Looking forward to improving #radonc #meded throughout my career ☢️💪

StephDudzinski's tweet image. My ❤️ always leaves happier after leaving @ASTRO_org conferences 

#ASTRO25 had many great things, but the best part was the people 👯‍♀️

🙏🏻 you again to @ARRO_org for the Resident Educator of the year award! 

Looking forward to improving #radonc #meded throughout my career ☢️💪
StephDudzinski's tweet image. My ❤️ always leaves happier after leaving @ASTRO_org conferences 

#ASTRO25 had many great things, but the best part was the people 👯‍♀️

🙏🏻 you again to @ARRO_org for the Resident Educator of the year award! 

Looking forward to improving #radonc #meded throughout my career ☢️💪
StephDudzinski's tweet image. My ❤️ always leaves happier after leaving @ASTRO_org conferences 

#ASTRO25 had many great things, but the best part was the people 👯‍♀️

🙏🏻 you again to @ARRO_org for the Resident Educator of the year award! 

Looking forward to improving #radonc #meded throughout my career ☢️💪
StephDudzinski's tweet image. My ❤️ always leaves happier after leaving @ASTRO_org conferences 

#ASTRO25 had many great things, but the best part was the people 👯‍♀️

🙏🏻 you again to @ARRO_org for the Resident Educator of the year award! 

Looking forward to improving #radonc #meded throughout my career ☢️💪

Loading...

Something went wrong.


Something went wrong.


United States Trends